MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback